Analysis of phenprocoumon and its hydroxylated and conjugated metabolites in human urine by high-performance liquid chromatography after solid-phase extraction.
The anticoagulant phenprocoumon is mainly metabolized in humans to hydroxylated metabolites and their glucuronides. A method is described for the determination of phenprocoumon, 4'-hydroxyphenprocoumon, 6-hydroxyphenprocoumon, 7-hydroxyphenprocoumon, and their glucuronide and sulphate conjugates in human urine. Reversed-phase high-performance liquid chromatography is performed after selective extraction with disposable quaternary amine columns of untreated, and beta-glucuronidase- or sulphatase-treated urine samples. Urinary excretion data are presented for total, glucuronidated, sulphated and free phenprocoumon, 4'-hydroxyphenprocoumon, 6-hydroxyphenprocoumon and 7-hydroxyphenprocoumon in twelve patients after an average daily dosage of 1.3-4.2 mg phenprocoumon.
Edelbroek
P M
PM
Toxicology Laboratory, University Hospital, Leiden, The Netherlands.
van Kempen
G M
GM
Hessing
T J
TJ
de Wolff
F A
FA
D000328:Adult; D000368:Aged; D002851:Chromatography, High Pressure Liquid; D005966:Glucuronidase; D006801:Humans; D006868:Hydrolysis; D006923:Hymecromone / Q000031:analogs & derivatives; D007202:Indicators and Reagents; D008297:Male; D008875:Middle Aged; D010644:Phenprocoumon / Q000652:urine*; D013056:Spectrophotometry, Ultraviolet; D013429:Sulfatases
D007202:Indicators and Reagents; C019492:4-methylumbelliferyl sulfate; D006923:Hymecromone; C034888:4-methylumbelliferyl glucuronide; D013429:Sulfatases; D005966:Glucuronidase; D010644:Phenprocoumon